EverSource Wealth Advisors’s Perspective Therapeutics CATX Stock Holding History

EverSource Wealth Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102	Sell	30 -5	-14%	-$19	﹤0.01%	4303
2026 Q1	$146	Buy	35 +34	+3,400%	+$144	﹤0.01%	4231
2025 Q4	$3	Sell	1 -870	-100%	-$2.48K	﹤0.01%	4260
2025 Q3	$2.99K	Hold	871	–	–	﹤0.01%	3378
2025 Q2	$3K	Buy	871 +850	+4,048%	+$2.24K	﹤0.01%	3351
2025 Q1	$45	Buy	+21	New	+$63	﹤0.01%	3905

Other funds holding CATX

NWMG

Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return

WIM

WealthPlan Investment Management Omaha, Nebraska $2.01B AUM 27.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

TWM

Trueblood Wealth Management Lima, Ohio $286M AUM 27.34% 1-Year Est. Return

TMWM

Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

KWM

Koa Wealth Management Encinitas, California $147M AUM 18.41% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

EverSource Wealth Advisors's CATX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Perspective Therapeutics (CATX) stake by 14% in Q2 2026, selling an estimated $19 and leaving 30 shares worth $102. The position accounts for ﹤0.01% of the portfolio, ranked #4303.

EverSource Wealth Advisors first reported a position in CATX in Q1 2025 and has held it in 6 quarters since. The position peaked at $3K in Q2 2025. 27 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

EverSource Wealth Advisors held 30 shares of Perspective Therapeutics worth $102 as of Q2 2026.
EverSource Wealth Advisors sold 5 Perspective Therapeutics shares in Q2 2026, an estimated $19.
Perspective Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4303 holding.
EverSource Wealth Advisors first reported a position in Perspective Therapeutics in Q1 2025 and has held it in 6 quarters since.
EverSource Wealth Advisors's Perspective Therapeutics position peaked at $3K in Q2 2025.
27 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.